<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0303256968
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMURAN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZATHIOPRINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        101.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GMBH CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GMBH CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;</strong><strong>What </strong><strong>Imuran Tablets </strong><strong>are </strong><strong>and what </strong><strong>they are</strong><strong> used for</strong></p><p>Imuran tablets contain the active substance azathioprine. They belong to a group of medicines called immunosuppressives. This means that they reduce the strength of your immune system.</p><p>Imuran Tablets may be used to help your body accept an organ transplant, such as a new kidney, heart or liver, or to treat some diseases where your immune system is reacting against your own body (autoimmune diseases).</p><p>Autoimmune diseases may include:</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rheumatoid arthritis (a disease where the immune system attacks cells lining the joints causing swelling, pain, stiffness of the joints),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic lupus erythematosus (a disease where the immune system attacks many of the body&#39;s organs and tissues, including skin, joints, kidneys, brain, and other organs causing severe fatigue, fever, stiffness and joint pain),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dermatomyositis and polymyositis (a group of diseases causing inflammation of the muscles, muscle weakness and skin rash),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; auto-immune chronic active hepatitis (a disease in which the immune system attacks liver cells causing liver inflammation, fatigue, muscle aches, yellowing of the skin and fever),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pemphigus vulgaris (a disease in which the immune system attacks skin cells causing severe blistering of the skin, mouth, nose, throat and genitals),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polyarteritis nodosa (a rare disease that causes inflammation of the blood vessels),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; auto-immune haemolytic anaemia (a serious blood disorder where the body destroys red blood cells quicker than it can produce them, with symptoms of weakness and shortness of breath),</p><p>‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic refractory idiopathic thrombocytopenic purpura (a condition with low platelet counts, that can cause easy or excessive bruising and bleeding).</p><p>Imuran Tablets may also be used to treat inflammatory bowel disease (Crohn&#39;s disease or ulcerative colitis).</p><p>Your doctor has chosen this medicine to suit you and your condition.</p><p>Imuran Tablets may be used on its own, but it is more often used in combination with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Imuran Tablets</strong></p><p><strong>Do not take Imuran Tablets:</strong></p><ul><li>&nbsp;if you are allergic to azathioprine or any of the other ingredients of this medicine (listed in section 6)</li><li>&nbsp;if you are allergic to mercaptopurine (a medicine which is similar to azathioprine the active substance contained in Imuran Tablets</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Imuran Tablets:</p><ul><li>&nbsp;if you have recently received, or are due to receive, a vaccination (vaccine). If you take Imuran Tablets, you should not have a live organism vaccine (for example; flu vaccine, measles vaccine, BCG vaccine, etc.) until advised it is safe to do so by your doctor. This is because some vaccines may give you an infection if you receive them while you are taking Imuran Tablets</li><li>&nbsp;if you have a genetic condition known as Lesch-Nyhan Syndrome. This is a rare condition that runs in families caused by a lack of something called HPRT or &lsquo;hypoxanthine-guanine-phosphoribosyltransferase&rsquo;.</li><li>if you have liver or kidney problems</li><li>if you have a genetic condition called TPMT deficiency (where your body produces too little of an enzyme called thiopurine methyltransferase)</li><li>&nbsp;if you have ever had chickenpox or shingles</li><li>&nbsp;if you have had hepatitis B (a liver disease caused by a virus)</li><li>&nbsp;if you are going to have an operation (this is because medicines including tubocurarine, or succinylcholine used as muscle relaxants during operations may interact with Imuran Tablets. You should inform your anaesthesiologist of your treatment with Imuran Tablets prior to surgery.</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse, or pharmacist before taking Imuran Tablets.<br />Your doctor will want to take<strong> regular blood samples </strong>while you are taking Imuran Tablets, to check for any changes (see section 3 &ldquo;How to take Imuran Tablets. The frequency of your blood tests will usually decrease the longer you continue to take Imuran Tablets.</p><p>If you are receiving immunosuppressive therapy, taking Imuran could put you at greater risk of:<br />&bull; tumours, including skin cancer. Therefore, when taking Imuran, avoid excessive exposure to sunlight, wear protective clothing and use protective sunscreen with a high protection factor.<br />&bull; lymphoproliferative disorders</p><p>o treatment with Imuran increases your risk of getting a type of cancer called lymphoproliferative disorder. With treatment regimen containing multiple immunosuppressants (including thiopurines), this may lead to death.<br />o A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV)-associated lymphoproliferative disorders).</p><ul><li>&nbsp;developing a serious condition called Macrophage Activation Syndrome (excessive activation of white blood cells associated with inflammation), which usually occurs in people who have certain types of arthritis, severe chickenpox, or shingles infection.</li><li>Therefore, when taking Imuran Tablets, avoid contact with people who have chickenpox or shingles.</li><li>a previous hepatitis B infection becoming active again</li><li>other infections such as PML (Progressive Multifocal Leukoencephalopathy) which is an opportunistic infection. If you experience any signs of infection, please contact your doctor (see section 4 &ldquo;Possible side effects&rdquo;).</li></ul><p><strong>Other medicines and Imuran Tablets</strong></p><p><strong>Tell your doctor if you are taking, have recently taken or might take any other medicines. This is because Imuran Tablets can affect the way some medicines work. Also, some other medicines can affect the way Imuran works. In particular tell your doctor if you are taking, or are planning to take:</strong></p><ul><li>&nbsp;ribavirin (used to treat viral infections)</li><li>methotrexate (mainly used to treat cancers)</li><li>allopurinol, oxipurinol, thiopurinol or other xanthine oxidase inhibitors, such as febuxostat (mainly used to treat gout)</li><li>&nbsp;penicillamine (mainly used in the treatment of rheumatoid arthritis)</li><li>ACE inhibitor (mainly used to treat high blood pressure &ndash; hypertension)</li><li>anticoagulants such as warfarin or acenocoumarol (used to prevent blood clots)</li><li>&nbsp;cimetidine (used to treat stomach ulcers and indigestion)</li><li>&nbsp;indomethacin (used as a pain killer and anti-inflammatory)</li><li>&nbsp;cytostatic drugs (drugs used to treat various types of cancer)</li><li>aminosalicylates e.g. olsalazine, mesalazine or sulfasalazine (mainly used in the treatment of ulcerative colitis and Crohn&rsquo;s disease)</li><li>co-trimoxazole (an antibiotic, used to treat infections caused by bacteria)</li><li>&nbsp;infliximab (mainly used in the treatment of ulcerative colitis and Crohn&rsquo;s disease)</li><li>&nbsp;Before a surgical procedure tell the anesthesiologist that you are taking azathioprine because muscle relaxants used during anesthesia may interact with azathioprine</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Imuran Tablets.</p><p><strong>Having vaccines while you are taking Imuran Tablets</strong><br />If you are due to receive a vaccination (vaccine) speak to your doctor or nurse before you do so. If you take Imuran Tablets, you should not have a live vaccine (for example; flu vaccine, measles vaccine, BCG vaccine, etc.) until advised it is safe to do so by your doctor. This is because some vaccines may give you an infection if you receive them while you are taking Imuran Tablets.</p><p><strong>Imuran Tablets with food and drink</strong><br />You should take your medicine at least 1 hour before or 2 hours after having milk or dairy products.</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor for advice before taking this medicine.</p><p><strong>Pregnancy</strong><br />Reliable contraceptive precautions must be taken to avoid pregnancy whilst you or your partner is taking Imuran Tablets.</p><p>If you are pregnant your doctor will carefully consider whether you should take this medicine, based on the risks and benefits of treatment.</p><p><strong>Breast-feeding</strong><br />Small amounts of Imuran may pass into the breast milk. It is recommended that women receiving Imuran should avoid breastfeeding unless the benefits outweighs the potential risks to the child. Ask your doctor for advice before breastfeeding.</p><p><strong>Fertility</strong><br />The effects of Imuran Tablets on fertility are not known.</p><p><strong>Driving and using machines</strong><br />Imuran Tablets are not known to affect your ability to drive or use machinery. If you experience any side effect from this medicine, you may not be able to drive or operate machinery.</p><p><strong>Imuran Tablets contain lactose</strong><br />Imuran Tablets contain lactose monohydrate. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to take Imuran Tablets</strong><br />Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />The quantity of Imuran Tablets taken may vary from patient to patient and will be prescribed by your doctor. The dose depends on the condition for which you are being treated.<br />You can take Imuran Tablets with food or on an empty stomach, but the choice of method should be consistent from day to day. Some patients feel nausea (sick) when first given Imuran Tablets, this may be relieved by taking the tablets after food.</p><ul><li>When you take Imuran Tablets, your doctor will take regular blood tests. This is to check the number and type of cells in your blood, and to ensure your liver is working correctly</li><li>Your doctor may also ask for other blood and urine tests to monitor how your kidneys are working and to measure uric acid levels. Uric acid is a natural substance made in your body and levels of uric acid can rise while you are taking Imuran Tablets. High levels of uric acid may damage your kidneys</li></ul><p>Your doctor may sometimes change your dose of Imuran Tablets as a result of these tests.</p><p>Swallow your tablets whole. Do not chew the tablets. The tablets should not be broken or crushed.</p><p>It is important that carers are aware of the need for safe handling of this medicine. If you or your caregiver does handle broken tablets, wash your hands immediately. Please consult your doctor or pharmacist for advice.</p><ul><li>Imuran should be initiated and supervised by a physician experienced in immunosuppressive therapy.</li><li>&nbsp;Imuran is a hazardous drug. Need caution when handling Imuran to minimize risk of exposure.</li><li>&nbsp;Personal not taking Imuran should not be exposed to it.</li></ul><p><strong>The recommended dose is:</strong></p><p><strong>Adults who have had an organ transplant: </strong>On the first day of treatment, the usual dose is up to 5 mg per kilogram of body weight, then a usual daily dose of 1 mg to 4 mg per kilogram of body weight. During treatment your doctor will adjust the dose depending on your reaction to the medicine.</p><p><strong>Adults with other conditions: </strong>The usual starting dose is 1 mg to 3 mg per kilogram of body weight, then a usual daily dose of less than 1 mg to 3 mg per kilogram of body weight During treatment your doctor will adjust the dose depending on your reaction to the medicine.</p><p>Elderly patients may need a reduced dose.</p><p>Patients with kidney or liver problems may need a reduced dose.</p><p><strong>Use in children</strong></p><p><strong>Children who have had organ transplant: </strong>The dosing for children who have had an organ transplant is the same as adults.</p><p><strong>Children with other conditions:</strong> The dosing for children with other conditions is the same as adults.</p><p>Children who are considered overweight may require a higher dose.</p><p><strong>If you take more Imuran Tablets than you should</strong><br />If you take too many tablets, contact your doctor or pharmacist<strong> immediately.</strong></p><p><strong>If you forget to take Imuran Tablets</strong><br />Do not take a double dose to make up for the dose that you missed. Inform your doctor if you do miss a dose.</p><p>If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise, take it as soon as you remember, then go back to taking it as you would normally.</p><p><strong>If you stop taking Imuran Tablets</strong><br />Before you stop taking Imuran Tablets, consult with your doctor or pharmacist. Do not stop taking Imuran Tablets until your doctor tells you it is safe to do so.</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong><br />Like all medicines, Imuran Tablets can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p><strong>Stop taking Imuran Tablets and see a doctor straight away, if you notice any of the following serious side effects, you may need urgent medical treatment:</strong></p><ul><li>&nbsp;allergic reactions, (these are uncommon side effects which may affect up to 1 in 100 people) the signs may include:</li></ul><p>o general tiredness, dizziness, feeling sick (nausea), being sick (vomiting), diarrhoea or abdominal pain<br />o swelling of the eyelids, face, or lips<br />o redness of the skin, skin nodules or a skin rash (including blisters, itching, or peeling skin)<br />o pain in the muscles or joints<br />o sudden wheeziness, coughing or difficulty breathing<br />In severe cases these reactions may be life-threatening (this is rare which may affect up to 1 in 10,000 people).</p><ul><li>Skin rashes or redness, which may develop into life-threatening skin reactions including widespread rash with blisters and peeling skin, particularly occurring around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome), extensive peeling of the skin (toxic epidermal necrolysis) (these may be very rare side effects which may affect up to 1 in 10,000 people)</li><li>Reversible pneumonitis (inflammation of your lungs causing breathlessness, cough, and fever) (these may be very rare side effects which may affect up to 1 in 10,000 people)</li><li>&nbsp;problems with your blood and bone marrow, signs include weakness, tiredness, paleness, bruising easily, unusual bleeding or infections (these may be very common side effects which may affect more than 1 in 10 people)</li><li>when Imuran Tablets is used in combination with other immunosuppressives you may get a virus which causes damage to your brain. This may cause headaches, changes in behaviour, impaired speech, worsening of abilities such as memory, attention and decision making (cognitive decline) and may be fatal (condition known as JC virus associated Progressive Multifocal Leukoencephalopathy) (these may be very rare side effects which may affect more than 1 in 10,000 people)</li></ul><p><strong>If you get any of the following serious side effects, talk to your doctor or specialist doctor immediately, you may need urgent medical treatment:</strong></p><ul><li>&nbsp;you have a high temperature (fever) or other signs of an infection such as sore throat, sore mouth, urinary problems, or chest infection causing breathlessness and cough (these may be very common side effects which may affect more than 1 in 10 people)</li><li>problems with your liver, signs include your skin, or the whites of your eyes turn yellow (jaundice) (these may be uncommon side effects which may affect up to 1 in 100 people)</li><li>various types of cancers including blood, lymph, and skin cancers (see section 2 Warnings and precautions) (these may be rare side effects which may affect up to 1 in 1000 people).</li><li>Sweet&rsquo;s syndrome (also known as acute febrile neutrophilic dermatosis). You may develop a rash (raised red, pink, or purple lumps which are sore to touch), particularly on your arms, hands, fingers, face and neck, which may also be accompanied by a fever (high temperature) (the rate at which these side effects occur is not known &ndash; cannot be estimated from available data)</li><li>&nbsp;a certain type of lymphomas (hepatosplenic T-cell lymphoma). You may develop nose bleeds, fatigue, significant night sweats, weight loss and unexplained fevers (high temperature) (the rate at which these side effects occur is not known &ndash; cannot be estimated from available data)</li></ul><p>If you notice any of the above, stop taking Imuran Tablets and see a doctor straight away.</p><p><strong>Other side effects include:</strong><br /><strong>Very Common (may affect more than 1 in 10 people)</strong></p><ul><li>&nbsp;low white blood cell level in your blood tests, which may cause an infection</li></ul><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>&nbsp;nausea (feeling sick)</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>&nbsp;anaemia (low red blood cell level)</li><li>&nbsp;pancreatitis (inflammation of the pancreas), which may cause severe upper stomach pain,</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>You might notice some hair loss while taking Imuran Tablets. Often hair does grow again, even if you carry on taking Imuran Tablets. If you are worried ask your doctor.</li></ul><p><strong>Very Rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>problems with your bowels leading to diarrhoea, abdominal pain, constipation, feeling or being sick (bowel perforation)</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>&nbsp;photosensitivity (sensitivity to light or sunlight)</li><li>&nbsp;You may develop a rash (raised red, pink, or purple lumps which are sore to touch), particularly on your arms, hands, fingers, face, and neck, which may also be accompanied by a fever (Sweet&rsquo;s syndrome, also known as acute febrile neutrophilic dermatosis). The rate at which these side effects occur is not known (cannot be estimated from available data).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Imuran</strong></p><ul><li>&nbsp;Do not store above 30&deg;C.</li><li>&nbsp;Protect from light.</li><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use Imuran after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</li><li>&nbsp;Imuran is a cytotoxic drug; need caution when handling to minimize risk of exposure.</li><li>The tablets should not be divided, broken or crushed.</li><li>Transport and store medicine in the original container or blister.</li><li>&nbsp;For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup.</li><li>People who are not taking medication should not be exposed to it.</li><li>&nbsp;Caution should be observed in handling broken or crushed tablets Avoid direct contact of the Imuran with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>Pregnant should avoid exposure to Imuran tablets.</li><li>Family members use gloves when handling laundry or cleaning within or around toilets.</li><li>&nbsp;Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving Imuran. If available, use separate bathroom from family members.</li><li>Conduct double washing of linens and wash them separately from other family laundry.</li><li>If your doctor tells you to stop taking the medication, or if it expired. Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines.</li><li>These measures will help protect environment.</li><li>Only keep the medicine if your doctor tells you to.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Imuran contains</strong></p><ul><li>The active substance is azathioprine.</li><li>The other ingredients are lactose monohydrate, pregelatinised starch, maize starch, stearic acid, magnesium stearate, methyl hydroxypropyl cellulose, and propylene glycol 400,purified water.</li><li>There is no colouring in the yellow tablets.</li><li>&nbsp;The colouring in the orange tablets contains titanium dioxide (E171), iron oxide yellow (E172) and iron oxide red (E172).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imuran tablets are covered by a thin coating and come in two strengths and colours;
Orange, round, biconvex, film-coated tablets, unscored, branded ‘IM 2’ and containing 25 mg Azathioprine BP in each tablet.
Yellow, round, biconvex, film-coated tablets, scored, branded ‘IM 5’ and containing 50 mg Azathioprine BP in each tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation Holder:</strong><br />Aspen Pharma Trading Limited<br />3016 Lake Drive,<br />Citywest Business Campus,<br />Dublin 24, Ireland</p><p><strong>Manufacturer:</strong><br />EXCELLA GmbH &amp; Co. KG, N&uuml;rnberger Strasse 12, 90537, Feucht, Germany</p><p><strong>Manufacturer:</strong><br />Aspen SA Operations (Pty) Ltd.,<br />Corner of Fairclough Road &amp; Gibaud Road,<br />Korsten, Gqeberha<br />6020, Republic of South Africa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {November/ 2022}, Version number {6}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1</strong><strong>. ما هي أقراص إميوران وما هي دواعي استعمالها</strong></p><p dir="RTL">تحتوي<strong><em> </em></strong>أقراص إميوران على المادة الفعالة ازاثيوبرين. وهي تنتمي إلى مجموعة من الأدوية يطلق عليها &quot;كابتات المناعة&quot;، وهذا يعني أنها تضعف قوة جهازك المناعي.</p><p dir="RTL">قد تستخدم أقراص إميوران لمساعدة الجسم على تقبل زراعة الأعضاء، مثل كلية جديدة، أو قلب جديد أو كبد جديد، أو لعلاج بعض الأمراض حيث يتفاعل جهاز المناعة ضد الجسم (أمراض المناعة الذاتية).</p><p dir="RTL">أمراض المناعة الذاتية قد تتضمن:</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الروماتويدي الحاد (مرض يهاجم فيه جهاز المناعة الخلايا المبطنة للمفاصل مسبباً تورم وألم، وتصلب المفاصل)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية المجموعية (مرض يهاجم فيه جهاز المناعة العديد من أعضاء وأنسجة الجسم، بما في ذلك الجلد، والمفاصل، والكليتين، والمخ، وأعضاء أخرى مسبباً إجهاد شديد، وحمى، وتصلب وألم بالمفاصل)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العضلات والجلد والتهاب العضلات (مجموعة من الأمراض تسبب التهاب العضلات وضعف العضلات وطفح جلدي)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الكبدي المناعي الذاتي النشط المزمن (مرض يهاجم فيه الجهاز المناعي خلايا الكبد مسبباً التهاب الكبد، والإجهاد، وآلام العضلات، واصفرار الجلد والحمى)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفقاع الشائع (مرض يهاجم فيه جهاز المناعة خلايا الجلد مسبباً بثور وتقرحات مؤلمة حادة على الجلد والفم والأنف والحلق والأعضاء التناسلية)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشرايين العقدي المتعدد (مرض نادر يسبب التهاب الأوعية الدموية)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الانحلالي المناعي الذاتي (اضطراب خطير في الدم، حيث يدمر الجسم خلايا الدم الحمراء بسرعة أكبر من مقدرته على إنتاجها، ويصحبه أعراض تتضمن الضعف وضيق التنفس)،</p><p dir="RTL">‒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفرفرية القليلة الصفيحات المجهولة السبب الحرون المزمنة (وهي حالة ينخفض بها عدد الصفائح الدموية، مما قد يتسبب في سهولة أو فرط التكدم والنزف)</p><p dir="RTL">يمكن استخدام أقراص إميوران أيضاً لعلاج مرض التهاب الأمعاء (مرض كرون أو التهاب القولون التقرحي)</p><p dir="RTL">لقد اختار طبيبك هذا الدواء لأنه يناسبك ويناسب حالتك.</p><p dir="RTL">يمكن استخدام أقراص إميوران وحدها، ولكنها تستخدم غالباً إلى جانب أدوية أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2. ما الذي يجب أن تعرفه قبل تناول أقراص</strong> <strong>إميوران</strong>.<strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتناول أقراص إميوران:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت تعاني من حساسية لمادة ازاثيوبرين أو لأي من مكونات الدواء الأخرى (المذكورة في القسم 6)،</li><li>&nbsp; إذا كنت تعاني من حساسية لمادة الميركابتوبيورين (وهو دواء مشابه للازاثيوبرين، المادة الفعالة التي تحتويها أقراص إميوران).</li></ul><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول أقراص إميوران:</p><ul dir="rtl"><li>&nbsp; &nbsp; إذا كنت قد تلقيت مؤخراً أو من المقرر أن تتلقى تطعيماً (لقاح). إذا كنت تتناول أقراص إميوران، يجب عليك الامتناع عن تلقي التطعيمات الحية التي تحتوي على كائنات حية (على سبيل المثال، لقاح الإنفلونزا، لقاح الحصبة، لقاح عصية كالميت غيران (السل) (BCG)، إلخ) حتى ينصحك الطبيب بأن القيام بذلك آمن. وذلك لأن بعض اللقاحات قد تصيبك بالعدوى إذا تلقيتها أثناء تناولك لأقراص إميوران.</li><li>&nbsp; &nbsp; &nbsp;إذا كنت مصاباً بحالة وراثية تعرف بمتلازمة ليش نيهان. وهي حالة نادرة تتوارث في العائلات وتنتج عن نقص إنزيم يُدعى HPRT أو &quot;إنزيم ناقلة الهيبوزانتين- جوانين- الفسفوريبوزيل&quot;.</li><li>&nbsp; &nbsp; إذا كنت مصاباً بمشكلات في الكبد أو الكلى.</li><li>&nbsp; &nbsp; إذا كنت مصاباً بحالة وراثية تعرف بنقص TPMT (حيث ينتج جسمك كمية ضئيلة للغاية من إنزيم يدعى إنزيم ناقلة الثيوبورين ميثيل)</li><li>&nbsp; &nbsp; إذا أصبت من قبل بجدري الماء أو الحزام الناري.</li><li>&nbsp; &nbsp;إذا أصبت من قبل بالالتهاب الكبدي ب (مرض كبدي فيروسي)</li><li>&nbsp; &nbsp;إذا كنت ستخضع لعملية جراحية (ذلك لأن أدوية مثل التوبوكورارين أو السكسينيل كولين التي تستخدم كمرخيات للعضلات أثناء العمليات الجراحية قد تتفاعل مع أقراص إميوران. يجب أن تخبر أخصائي التخدير أنك تتناول العلاج بأقراص إميوران قبل الخضوع للجراحة.</li></ul><p dir="RTL">إن لم تكن متأكداً من أن أياً مما ورد أعلاه ينطبق عليك، أستشر طبيبك أو الممرضة أو الصيدلي قبل تناول أقراص إميوران .</p><p dir="RTL">سيرغب طبيبك في أخذ <strong>عينات دم منتظمة</strong> خلال فترة العلاج بأقراص إميوران، للتحقق من حدوث أي تغيرات (راجع القسم 3 &quot;كيفية تناول أقراص إميوران&quot;). عادة ما يقل تكرار إجراء اختبارات الدم كلما طالت فترة العلاج بأقراص إميوران.</p><p dir="RTL">إذا كنت تتلقى علاجاً كابتاً للمناعة، فإن تناول إميوران يجعلك أكثر عرضة للإصابة بـ:</p><ul dir="rtl"><li>&nbsp; &nbsp; الأورام، بما في ذلك سرطان الجلد. لذا، عند تناول إميوران، تجنب التعرض لضوء الشمس لفترات طويلة، وارتد ملابساً واقية واستخدم مستحضراً واقياً من الشمس بمعامل حماية مرتفع.</li><li>&nbsp; &nbsp; الاضطرابات التكاثرية اللمفية:</li></ul><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج بإميوران يرفع خطر الإصابة بنوع من السرطان يدعى الاضطراب التكاثري اللمفي. قد يؤدي اتباع نظام علاجي يحتوي على كابتات مناعة متعددة (بما في ذلك زمرة الثيوبورين) إلى الوفاة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرفع الجمع ما بين كابتات مناعة متعددة، حين يتم تناولها في نفس الوقت، احتمال الإصابة باضطرابات الجهاز اللمفاوى بسبب العدوى الفيروسية (الاضطرابات التكاثرية اللمفية المرتبطة بفيروس إبشتاين-بار (EBV) ).</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;الإصابة بحالة خطيرة تدعى متلازمة تنشيط البلاعم (تنشيط مفرط لخلايا الدم البيضاء مرتبط بالالتهاب)، تحدث عادة عند الأشخاص المصابين بأنواع محددة من التهاب المفاصل أو عدوى حادة بجدري الماء أو الحزام الناري.</li><li>&nbsp; &nbsp; لذا، خلال فترة العلاج بأقراص إميوران، تجنب التواصل مع المصابين بجدري الماء أو الحزام الناري.</li><li>&nbsp; &nbsp; قد تنشط لديك إصابة سابقة بالالتهاب الكبدي ب</li><li>&nbsp; عدوى بأمراض أخرى مثل اعتلال بيضاء الدماغ متعدد البؤر المترقي (PML) وهو عدوى انتهازية. إذا ظهرت أي علامات على الالتهاب، يُرجى الاتصال بطبيبك (راجع قسم 4 &quot;الآثار الجانبية المحتملة&quot;).</li></ul><p dir="RTL"><strong>الأدوية الأخرى وأقراص إميوران</strong></p><p dir="RTL"><strong>أخبر طبيبك إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. هذا لأن أقراص إميوران يمكن أن تؤثر على آلية عمل بعض الأدوية الأخرى. كما يمكن للأدوية الأخرى أن تؤثر على آلية عمل أقراص إميوران. أخبر طبيبك إن كنت تتناول، أو تخطط لتناول أي من الأدوية التالية على وجه الخصوص: </strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;ريبافيرين (يستخدم لعلاج العدوى الفيروسية).</li><li>&nbsp;ميثوتريكسيت (يستخدم بشكل رئيسي لعلاج السرطانات)</li><li>&nbsp; &nbsp;ألوبيورينول، أوكسيبيورينول، ثيوبيورينول أو مثبطات أكسيداز الزانثين الأخرى، مثل فيبوكسوستات ( يستخدم بشكل رئيسي في علاج النقرس)</li><li>&nbsp; &nbsp;بنسيلامين (يستخدم بشكل رئيسي في علاج التهاب المفاصل الروماتويدي)</li><li>&nbsp; &nbsp; مثبط الإنزيم المحول للأنجيوتنسين (ACE) (يستخدم بشكل رئيسي في علاج ضغط الدم المرتفع (ارتفاع ضغط الدم)).</li><li>&nbsp; &nbsp;مضادات التخثر مثل وارفارين أو أسينوكومارول (يستخدم لمنع تكون جلطات الدم)</li><li>&nbsp; سيميتدين- (يُستخدم لعلاج قرح المعدة وعسر الهضم)</li><li>&nbsp; &nbsp;إندوميثاسين (يستخدم كمسكن للألم ومضاد للالتهابات)</li><li>&nbsp; &nbsp;عقاقير السايتوستاتيك (تستخدم في علاج مختلف أنواع السرطان)</li><li>&nbsp; &nbsp; الأمينوساليسيلات، مثل أولسالازين، أو ميسالازين، أو سالفاسالازين (تستخدم بشكل رئيسي في علاج التهاب القولون التقرحي أو مرض كرون)</li><li>&nbsp; &nbsp;كوتريموكسازول (مضاد حيوي، يستخدم لعلاج الالتهابات التي تتسبب بها البكتريا)</li><li>&nbsp; &nbsp; &nbsp;إينفليكسيماب (يُستخدم بشكل رئيسي في علاج التهاب القولون التقرحي و مرض كرون)</li><li>&nbsp; مرخيات العضلات، على سبيل المثال توبوكورارين أو سوكسنيل كولين (يستخدمان أثناء العمليات) حيث أنها قد تتفاعل مع أقراص إميوران. يجب أن تخبر أخصائي التخدير أنك تتناول العلاج بأقراص إميوران قبل الخضوع للجراحة..</li><li>&nbsp; قبل الخضوع لإجراء جراحي، أخبر أخصائي التخدير أنك تتناول أزاثيوبرين حيث أن مرخيات العضلات المستخدمة أثناء التخدير قد تتفاعل مع أزاثيوبرين.</li></ul><p dir="RTL">إن لم تكن متأكداً من أن أياً مما ورد أعلاه ينطبق عليك، أستشر طبيبك أو الصيدلي قبل تناول أقراص إميوران .</p><p dir="RTL"><strong>تلقي التطعيمات أثناء تناولك أقراص إميوران</strong></p><p dir="RTL">إذا كان من المقرر أن تتلقى تطعيماً، تحدث إلى طبيبك أو الممرضة قبل تلقيه. إذا كنت تتناول أقراص إميوران، يجب عليك الامتناع عن تلقي التطعيمات الحية (على سبيل المثال، لقاح الإنفلونزا، لقاح الحصبة، لقاح عصية كالميت غيران (السل)(BCG)، إلخ) إلى أن يخبرك الطبيب أنه من الآمن تناول هذا الدواء. وذلك لأن بعض اللقاحات قد تصيبك بالعدوى إذا تلقيتها أثناء تناولك لأقراص إميوران.</p><p dir="RTL"><strong>أقراص إميوران مع الطعام والشراب</strong></p><p dir="RTL">ينبغي أن تتناول دواءك قبل ساعة واحدة أو بعد ساعتين على الأقل من شرب الحليب أو تناول منتجات الألبان.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك قبل تناول هذا الدواء.<strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب اتخاذ تدابير منع الحمل الموثوقة لتجنب حدوث الحمل إذا كنت أنت أو زوجك/ زوجتك تستخدم أقراص إميوران.</p><p dir="RTL">إذا كنت حاملاً، سينظر طبيبك بعناية إذا ما كان ينبغي أن تتناولي هذا الدواء، بناء على مخاطره ومنافعه.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">قد تمر كميات صغيرة من أقراص إميوران إلى حليب الثدي. توصى السيدات اللاتي يتناولن أقراص إميوران بتجنب الإرضاع عدا كانت فوائد العلاج تفوق المخاطر المحتملة على طفلك. أطلبي المشورة من طبيبك قبل إرضاع طفلك.<strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">آثار أقراص إميوران على الخصوبة غير معروفة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المتوقع أن تؤثر أقراص إميوران على قدرتك على القيادة أو استخدام الآلات. إذا ظهرت عليك أي من الآثار الجانبية لهذا الدواء، قد لا تتمكن من القيادة أو تشغيل الآلات.</p><p dir="RTL"><em>&nbsp;</em><strong>أقراص إيميوران تحتوي على اللاكتوز</strong></p><p dir="RTL">أقراص إيميوران تحتوي على لاكتوز أحادي الهيدرات. إذا أخبرك طبيبك أنك تعاني من عدم تحمل لبعض أنواع السكر، فعليك استشارته قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3. كيفية تناول أقراص إميوران</strong></p><p dir="RTL">تناول هذا الدواء دائماً على النحو الذي يصفه طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">قد تتباين كمية أقراص إميوران التي يجب تناولها من مريض لآخر، وسيصف لك الطبيب الجرعة. تعتمد الجرعة على الحالة التي تعالج منها.</p><p dir="RTL">يمكنك تناول أقراص إميوران مع الطعام أو على معدة خاوية، إلا أن الطريقة التي تختارها يجب أن تكون موحدة من يوم إلى الآخر . يشعر بعض المرضى بالغثيان (رغبة في القيء) في بادئ الأمر عند تناول أقراص إميوران، وقد يزول هذا الشعور إذا ما تم تناول الأقراص بعد الطعام.</p><ul dir="rtl"><li>&nbsp; &nbsp;سيقوم طبيبك بطلب فحوصات دم دورية خلال فترة علاجك بأقراص إميوران. وذلك لتفقد عدد ونوع الخلايا في الدم، ولضمان عمل الكبد بشكل سليم.</li><li>&nbsp; قد يطلب الطبيب أيضاً إجراء اختيارات دم أو بول أخرى لمراقبة كيفية عمل الكلى لديك ولقياس مستويات حمض اليوريك. حمض اليوريك مادة طبيعية ينتجها الجسم وقد يرتفع مستوى هذا الحمض في فترة العلاج بأقراص إميوران. قد يتسبب ارتفاع مستويات حمض اليوريك في تلف الكلى.</li></ul><p dir="RTL">قد يقوم طبيبك بتغيير جرعة أقراص إميوران بحسب نتائج هذه الفحوصات.</p><p dir="RTL">ابتلع القرص كاملاً. لا تمضغ الأقراص. لا ينبغي أن تكسر الأقراص أو تسحقها.</p><p dir="RTL">من الهام أن يعي مقدمو الرعاية الحاجة إلى التعامل الآمن مع هذا الدواء. إذا لمست أنت أو مقدم الرعاية أقراصاً مكسورة، يجب غسل اليدين على الفور. يرجى طلب المشورة من طبيبك أو الصيدلي.</p><ul dir="rtl"><li>&nbsp; &nbsp; يجب بدء استخدام إميوران والإشراف عليه من قبل طبيب خبير في العلاج المثبط للجهاز المناعي.</li><li>&nbsp; &nbsp; إميوران دواء خطير. ينبغي توخي الحذر عند التعامل مع إميوران للحد من مخاطر التعرض.</li><li>&nbsp; &nbsp;الشخص الذي لا يتناول إميوران يجب ألا يتعرض له.</li></ul><p dir="RTL"><strong>الجرعة الموصى بها:</strong></p><p dir="RTL"><strong>البالغون الذين خضغوا من قبل لعملية زرع أعضاء:</strong> في اليوم الأول من العلاج، تؤخذ عادة جرعة تصل إلى 5 ملغ لكل كيلو غرام من وزن الجسم، ثم تؤخذ جرعة يومية معتادة من 1 ملغ إلى 4 ملغ لكل كيلو غرام من وزن الجسم<strong>.</strong> خلال فترة العلاج، سيعدل الطبيب الجرعة بحسب استجابتك للدواء.</p><p dir="RTL"><strong>البالغون المصابون بحالات أخرى:</strong> تتراوح الجرعة الأولية عادة ما بين 1 ملغ إلى 3 ملغ لكل كيلو غرام من وزن الجسم، ثم عادة ما تكون الجرعة اليومية أقل من 1 ملغ إلى 3 ملغ لكل كليو غرام من وزن الجسم. خلال فترة العلاج، سيعدل الطبيب الجرعة بحسب استجابتك للدواء.</p><p dir="RTL">قد يحتاج المرضى كبار السن لخفض الجرعة.</p><p dir="RTL">قد يحتاج المرضى الذين يعانون من مشاكل بالكبد أو الكُلى لجرعة مخفضة.</p><p dir="RTL"><strong>الاستخدام في حالات الأطفال </strong></p><p dir="RTL"><strong>&nbsp;الأطفال الذين خضغوا من قبل لعملية زرع أعضاء :</strong> الجرعة للأطفال الذين خضغوا من قبل لعملية زرع الأعضاء هي ذاتها التي يتناولها البالغون.</p><p dir="RTL"><strong>الأطفال المصابون بحالات أخرى: </strong>الجرعة للأطفال المصابين بحالات أخرى هي ذاتها التي يتناولها البالغون.</p><p dir="RTL">قد يحتاج الأطفال الذين يعتبرون زائدي الوزن إلى جرعة أعلى.<strong>&nbsp;</strong></p><p dir="RTL"><strong>في حال تناول كمية أكثر من اللازم من أقراص إميوران</strong></p><p dir="RTL">إذا تناولت الكثير من الأقراص، اتصل بطبيبك أو الصيدلي على الفور .</p><p dir="RTL"><strong>إن نسيت تناول أقراص إميوران</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك. اخبر الطبيب إذا ما فوّت جرعة.</p><p dir="RTL">في حالة اقتراب موعد جرعتك التالية، تخطى الجرعة التي فاتتك وتناول جرعتك التالية في الموعد المحدد. عدا ذلك، تناول جرعتك بمجرد أن تتذكر، ثم ارجع إلى تناول الدواء على النحو المعتاد.</p><p dir="RTL"><strong>إذا توقفت عن تناول</strong><em> </em><strong>أقراص إميوران</strong></p><p dir="RTL">قبل الانقطاع عن تناول أقراص إميوران، استشر طبيبك أو الصيدلي. لا تتوقف عن تناول أقراص إميوران حتى يخبرك الطبيب أن القيام بذلك آمن.</p><p dir="RTL"><strong>إن كان لديك أي استفسارات أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4. الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن أن تسبب أقراص إميوران آثارًا جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع. قد تحدث الآثار الجانبية التالية مع تناول هذا الدواء:</p><p dir="RTL"><strong>توقف عن تناول</strong><em> </em><strong>أقراص إميوران واستشر طبيباً فوراً إذا لاحظت ظهور أي من الآثار الجانبية الخطيرة التالية، فربما تحتاج إلى علاج طبي عاجل:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;ردود فعل تحسسيه (هذه آثار جانبية غير شائعة قد تؤثر على1 من كل 100 شخص)، وقد تتضمن العلامات:</li></ul><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء عام، دوّار، الشعور بالغثيان (رغبة في القيء)، القيء أو الإسهال، أو ألم بالبطن</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون أو الوجه أو الشفتين</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد أوعقيدات الجلد أوطفح جلدي (بما في ذلك ظهور بثور، أو حكة أو تقشر الجلد)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزير مفاجئ، كحة أو صعوبة في التنفس</p><p dir="RTL">في حالات حادة قد تكون ردود الفعل هذه مهددة للحياة (نادرة جداً حيث قد تؤثر على 1 من كل 10000 شخص).</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;الاحمرار أو الطفح الجلدي، الذي قد يتحول إلى ردود فعل جلدية مهددة للحياة بما في ذلك انتشار الطفح مع بثور وتقرحات وتقشر الجلد، على الأخص التي تظهر حول الفم، والأنف، والعيون، والأعضاء التناسلية (متلازمة ستيفينز جونسون )، تقشر عميق بالجلد (تقشر الأنسجة المتموتة البشروية التسممي) (قد تكون هذه آثار جانبية نادرة للغاية حيث قد تؤثر على 1 من كل 10000 شخص)</li><li>&nbsp; &nbsp;التهاب رئوي قابل للعكس (التهاب يصيب الرئتين ويسبب انقطاع النفس، والكحة، والحمى) (قد تكون هذه آثار جانبية نادرة للغاية قد تؤثر على 1 من كل 10000 شخص)</li><li>&nbsp; &nbsp;مشكلات في الدم والنخاع العظمي، وقد تتضمن العلامات الضعف، والإعياء، والشحوب، وسهولة التكدم، وعدوى أو نزيف غير معتاد (قد تكون هذه آثار جانبية شائعة للغاية قد تؤثر على أكثر من 1 من كل 10 أشخاص)</li><li>&nbsp; &nbsp;عند استخدام أقراص إميوران بالإضافة إلى كابتات مناعة أخرى، قد تصاب بفيروس يتسبب بضرر الدماغ. وقد ينجم عن ذلك صداع، تغيرات في السلوك، ضعف الكلام، تدهور القدرات مثل الذاكرة، والانتباه والقدرة على اتخاذ القرارات (انخفاض الإدراك) وقد يكون مميتاً (حالة تعرف باسم اعتلال بيضاء الدماغ متعدد البؤر المترقي المرتبط بفيروس جيه سي (<em>JC virus</em>) (قد تكون هذه آثار جانبية نادرة للغاية قد تؤثر على 1 من كل 10000 شخص)</li></ul><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>ظهرت</strong><strong> </strong><strong>عليك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong><strong> </strong><strong>التالية،</strong><strong> </strong><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>طبيب</strong><strong> </strong><strong>أخصائي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong><strong>فقد</strong><strong> </strong><strong>تحتاج</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>طبي</strong><strong> </strong><strong>طارئ</strong><strong>.:</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;إذا عانيت من ارتفاع درجة الحرارة (الحمى) أو أي من علامات الالتهاب مثل التهاب الحلق، أو قرحة الفم، أو مشاكل بولية أو التهاب الصدر الذي يسبب انقطاع النفس والكحة (قد تكون هذه آثار جانبية شائعة للغاية قد تؤثر على أكثر من 1 من كل 10 أشخاص)</li><li>&nbsp; &nbsp; مشاكل بالكبد، وتتضمن العلامات اصفرار الجلد أو بياض العينين (يرقان) (قد تكون هذه آثار جانبية غير شائعة قد تؤثر على 1 من كل 100 شخص)</li><li>&nbsp; &nbsp; أنواع السرطان المختلفة بما في ذلك سرطان الدم، والغدد الليمفاوية، والجلد (راجع القسم 2 التحذيرات والاحتياطات) (قد تكون هذه آثار جانبية نادرة قد تؤثر على 1 من كل 1000 شخص)</li><li>&nbsp; &nbsp; &nbsp;متلازمة سويت (تعرف أبضاً بالجلاد الحموي الحاد بالعدلات) قد تصاب بطفح جلدي (كتل مرتفعة حمراء، أو وردية أو ارجوانية تكون مؤلمة عند لمسها)، خاصة على الذراعين، واليدين، والأصابع، والوجه، والرقبة، والتي قد تكون مصحوبة أيضاً بحمى (ارتفاع درجة الحرارة) (المعدل الذي تحدث به هذه الآثار الجانبية غير معروف- لا يمكن تقديره من البيانات المتوفرة)</li><li>&nbsp; &nbsp; &nbsp; متلازمة سويت (تعرف أبضاً بالجلاد الحموي الحاد بالعدلات) قد تصاب بطفح جلد (كتل مرتفعة حمراء، أو وردية أو ارجوانية تكون مؤلمة عند لمسها)، خاصة على الذراعين، واليدين، والأصابع، والوجه، والعنق، والتي قد تكون مصحوبة أيضاً بحمى (ارتفاع درجة الحرارة) (معدل حدوث هذه الآثار الجانبية غير معروف - لا يمكن تقديره من البيانات المتوفرة)</li><li>&nbsp; &nbsp;نوع معين من سرطان الغدد الليمفاوية (لمفومة كبدية طحالية تائية الخلايا). قد تصاب بنزيف من الأنف، إجهاد، تعرق ليلي غزير، فقدان وزن ونوبات حمى غير مبررة (ارتفاع درجة الحرارة) (المعدل الذي تحدث به هذه الآثار الجانبية غير معروف- لا يمكن تقديره من البيانات المتوفرة)</li></ul><p dir="RTL">إذا لاحظت أي من الأعراض المذكورة أعلاه، توقف عن تناول أقراص إميوران وأستشر طبيباً على الفور.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL"><strong>شائعة جداً (قد تؤثر على أكثر من </strong>1<strong> من كل </strong>10<strong> أشخاص):</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;انخفاض مستوى خلايا الدم البيضاء في فحوصات الدم الخاصة بك، مما قد يؤدي إلى الإصابة بالالتهاب.</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر على </strong>1<strong> من كل </strong>10<strong> أشخاص)</strong></p><ul dir="rtl"><li>&nbsp;الغثيان (شعور برغبة في القيء)</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على </strong>1<strong> من كل </strong>100<strong> شخص)</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;أنيميا (انخفاض مستوى كرات الدم الحمراء)</li><li>&nbsp; التهاب البنكرياس، الذي قد يؤدي إلى ألم شديد أعلى المعدة،</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على </strong>1<strong> من كل </strong>1000<strong> شخص)</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;قد تلاحظ بعض تساقط الشعر أثناء تناولك أقراص إميوران. غالباً ما ينمو الشعر مرة أخرى، حتى لو واصلت العلاج بأقراص إميوران. إن كنت تشعر بالقلق فاسأل بطبيبك .</li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر على </strong>1<strong> من كل </strong>10000<strong> شخص)</strong></p><ul dir="rtl"><li>&nbsp; اضطرابات في الأمعاء مما قد يؤدي إلى إسهال وألم في البطن وإمساك والشعور بالغثيان (رغبة في القيء) والقيء (ثقب الأمعاء)</li></ul><p dir="RTL"><strong>غير معروف (لا يمكن تقدير مدى التكرار من البيانات المتوفرة):</strong></p><ul dir="rtl"><li>&nbsp; تحسس ضوئي (حساسية للضوء أو أشعة الشمس)</li><li>&nbsp; &nbsp; &nbsp;قد تصاب بطفح جلدي (كتل مرتفعة حمراء، أو وردية أو ارجوانية تكون مؤلمة عند لمسها)، خاصة على الذراعين، واليدين، والأصابع، والوجه، والعنق، والتي قد تكون مصحوبة أيضاً بحمى (متلازمة سويت، والتي تعرف أيضاً بالجلاد الحموى الحاد بالعدلات). معدل حدوث هذه الآثار الجانبية غير معروف (لا يمكن تقديره من البيانات المتوفرة).</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. كيفية تخزين أقراص إميوران.</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;يخزن في درجة حرارة أقل من 30 درجة مئوية.</li><li>&nbsp; &nbsp; يحفظ في العبوة الأصلية لحمايته من الضوء.</li><li>&nbsp; يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</li><li>&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية الخارجية بعد عبارة &quot;تاريخ انتهاء الصلاحية&quot; (EXP). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</li><li>&nbsp; إميوران &nbsp;دواء سام للخلايا، وينبغي توخي الحذر عند التعامل معه للحد من مخاطر التعرض.</li><li>&nbsp; &nbsp;يجب ألا تُقسم الأقراص، أو تُكسر أو تُسحق.</li><li>&nbsp; &nbsp;يُنقل الدواء ويُخزن في الشريط أو الحاوية الأصلية.</li><li>&nbsp; &nbsp;لتقديم الدواء، تُستخدم القفازات وتُغسل اليدين جيداً قبل تقديم الدواء وبعده. في حالة عدم ارتداء القفازات، تقلب الأقراص من عبوتها/ الشريط مباشرة في كوب طبي يمكن التخلص منه.</li><li>&nbsp; &nbsp;الأشخاص الذين لا يتناولون الدواء يجب ألا يتعرضوا له.</li><li>&nbsp; &nbsp;يجب توخي الحذر عند التعامل مع أقراص مكسورة أو مسحوقة. تجنب التلامس المباشر لإميوران مع الجلد أو الأغشية المخاطية. في حالة حدوث التلامس، يُغسل موضع التلامس جيداً بالماء والصابون، وتُشطف العينين جيداً بماء معقم، أو ماء عادي في حالة عدم توفر الماء المعقم.</li><li>&nbsp; &nbsp; &nbsp;ينبغي على السيدات الحوامل تجنب التعرض لأقراص إميوران.</li><li>&nbsp; &nbsp; &nbsp;يجب على أفراد الأسرة استخدام القفازات عند التعامل مع الغسيل أو التنظيف داخل المراحيض أو حولها.</li><li>&nbsp; أغلق الغطاء قبل شد السيفون واسحبه مرتين بعد كل مرة بها يستخدم المريض المرحاض، وذلك لمدة 48 ساعة بعد تلقي <em>إميوران</em>. عند التوفر، استخدم حماماً منفصلاً عن الحمام الذي يستخدمه أفراد الأسرة.</li><li>&nbsp; &nbsp; يجب غسل البياضات غسلاً مزدوجاً وتغسل بشكل منفصل عن غسيل الأسرة الآخر.</li><li>&nbsp; &nbsp;إذا أخبرك الطبيب بالتوقف عن تناول الدواء، أو انتهت صلاحيته.&nbsp; لا تتخلص من الدواء في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، أو أعدها إلى الصيدلي الذي سيقوم بإتلافها وفقاً لإرشادات التخلص من المواد الخطرة.</li><li>&nbsp; &nbsp;ستساعد هذه الإجراءات في الحفاظ على البيئة.</li><li>&nbsp; &nbsp; &nbsp;احتفظ بالدواء فقط إذا أخبرك طبيبك بذلك.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي إميوران</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; المادة الفعالة هي ازاثيوبرين.</li><li>&nbsp; &nbsp;المكونات الأخرى هي مونوهيدرات اللاكتوز ، نشا مسبق التجلتن، نشا الذرة، حمض الستياريك، ستيارات المغنيسيوم وهيدروكسي بروبيل ميثيل السيللوز والبروبيلين جليكول 400.الماء المقطر</li><li>&nbsp; &nbsp; &nbsp;لا تحتوى الأقراص الصفراء على مواد مُلونة.</li><li>&nbsp; &nbsp; تحتوى المادة الملونة في الأقراص البرتقالية على ثاني أكسيد التيتانيوم (E171) وأكسيد الحديد الأصفر (E172) وأكسيد الحديد الأحمر (E172).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو دواء إميوران وما هي محتويات العبوة</strong></p><p dir="RTL">أقراص إميوران مُغطاة بطبقة رقيقة وتأتي بتركيزين ولونين مختلفين.</p><p dir="RTL">أقراص برتقالية مستديرة محدبة من الجانبين، غير محززة، وعليها العلامة التجارية &quot;IM 2&quot; وتحتوي 25 ملغ أزاثيوبرين وفقاً لدستور الأدوية البريطاني في كل قرص.</p><p dir="RTL">أقراص صفراء مستديرة محدبة من الجانبين، محززة وعليها العلامة التجارية &quot;IM 5&quot; وتحتوي 50 ملغ أزاثيوبرين وفقاً لدستور الأدوية البريطاني في كل قرص.</p><p dir="RTL">تتوفر أقراص إميوران في علب تحتوي على 100 قرص في شرائط (عبوات تحتوي 4 شرائط يحتوي كل منها على 25 قرصاً).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق والمُصَّنع</strong></p><p><strong>مالك حق التسويق:</strong><br />أسبن فارما تريدينغ المحدودة<br />3016 ليك درايف،<br />مجمع سيتي ويست للأعمال،&nbsp;<br />دبلن 24، أيرلندا</p><p><strong>المُصَّنع:</strong><br />شركة أكسيلا المحدودة وشركاها كي جي، 12 شارع نورنبرج، 90537، فويست، ألمانيا</p><p dir="RTL"><strong>المُصَّنع:</strong></p><p dir="RTL">أسبن إس أي أوبريشنز (بي تي واي) المحدودة</p><p dir="RTL">زاوية إلتقاء طريق فيرلوق مع طريق قيباود،</p><p dir="RTL">كورستن، جكيبرها، 6020</p><p dir="RTL">جمهورية جنوب إفريقيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في {نوفمبر/ 2022} ، رقم النسخة {6}.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imuran 50mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yellow, round, biconvex, film-coated tablets, scored, branded ‘IM 5’and containing 50 mg Azathioprine BP in each tablet.

Each tablet contains 50 mg of the active substance azathioprine.

Excipient(s) with known effect
Each 50 mg tablet contains 74 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1 Therapeutic Indications</strong></p><p>Azathioprine is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.</p><p>Azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients.</p><p>Azathioprine is indicated for the treatment of moderate to severe inflammatory bowel disease (IBD) (Crohn&rsquo;s disease or ulcerative colitis) in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy.&nbsp;</p><p>Azathioprine, either alone or more usually in combination with corticosteroids and/or other medicinal products and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following:</p><ul><li>&nbsp; severe rheumatoid arthritis;</li><li>&nbsp;systemic lupus erythematosus;</li><li>&nbsp; dermatomyositis and polymyositis;</li><li>&nbsp;auto-immune chronic active hepatitis;</li><li>&nbsp;pemphigus vulgaris;</li><li>&nbsp;polyarteritis nodosa;</li><li>auto-immune haemolytic anaemia;</li></ul><p>chronic refractory idiopathic thrombocytopenic purpura.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General: </u></p><p>Imuran should be initiated and supervised by a physician experienced in immunosuppressive therapy.</p><p><u>&nbsp;Posology</u><em>&nbsp;</em></p><p>When the oral route is impractical, azathioprine injection may be administered by the IV route only, however, this route should be discontinued as soon as oral therapy can be tolerated once more.</p><p>Specialist medical literature should be consulted for guidance as to clinical experience in particular conditions.</p><p><u>&nbsp;Populations</u></p><p><u>&nbsp;</u><em><u>Adults</u></em></p><p><em>Transplants</em></p><p>Depending on the immunosuppressive regimen employed, a dosage of up to 5mg/kg body weight/day may be given orally or intravenously on the first day of therapy.</p><p>Maintenance dosage should range from 1to 4 mg/kg body weight/day and must be adjusted according to clinical requirements and haematological tolerance.</p><p>Evidence indicates that azathioprine therapy should be maintained indefinitely, even if only low doses are necessary, because of the risk of graft rejection.</p><p><em>Other indications</em></p><p>In general, starting dosage is from 1 to 3 mg/kg body weight/day, and should be adjusted, within these limits, depending on the clinical response (which may not be evident for weeks or months) and haematological tolerance.</p><p>When therapeutic response is evident, consideration should be given to reducing the maintenance dosage to the lowest level compatible with the maintenance of that response. If no improvement occurs in the patient&rsquo;s condition within three months, consideration should be given to withdrawing azathioprine. However, for patients with IBD, a treatment duration of at least twelve months should be considered and a response to treatment may not be clinically apparent until after three to four months of treatment.</p><p>The maintenance dosage required may range from less than 1 mg/kg body weight/day to 3 mg/kg body weight/day, depending on the clinical condition being treated and the individual patient response, including haematological tolerance.</p><p><em>&nbsp;</em><em><u>Paediatric population</u></em></p><p><em>Transplants</em></p><p>The posology in children is the same as in adults (see Section 4.2 Adults &ndash; Transplants).</p><p><em>Other indications</em></p><p>The posology in children is the same as in adults (see Section 4.2 Adults <!--[if supportFields]><span
lang=EN-GB style='font-family:"Times New Roman",serif'><span style='mso-element:
field-begin'></span>SYMBOL 8722\u</span><![endif]--><!--[if supportFields]><span
lang=EN-GB style='font-family:"Times New Roman",serif'><span style='mso-element:
field-end'></span></span><![endif]--> Other Indications).</p><p><em>&nbsp;Overweight children</em></p><p>Children considered to be overweight may require doses at the higher end of the dose range and therefore close monitoring of response to treatment is recommended (see Section 5.2).</p><p><em>&nbsp;</em><em><u>Elderly population</u></em></p><p>There is limited experience of the administration of azathioprine to elderly patients. Although the available data do not provide evidence that the incidence of side effects among elderly patients is higher than that among other patients treated with azathioprine, it is advisable to monitor renal and hepatic function, and to consider dosage reduction if there is impairment (see Section 4.2).</p><p><em>&nbsp;</em><em><u>Renal impairment</u></em></p><p>Since azathioprine pharmacokinetics has not been formally studied in renal impairment, no specific dose recommendations can be given. Since impaired renal function may result in slower elimination of azathioprine and its metabolites, consideration should be given to reducing the starting doses in patients with impaired renal function. Patients should be monitored for dose related adverse effects (see Section 4.4 and section 5.2).</p><p><em><u>Hepatic impairment</u></em></p><p>Since azathioprine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given. Since impaired hepatic function may result in reduced elimination of azathioprine and its metabolites, consideration should be given to reducing the starting doses in patients with impaired hepatic function. Patients should be monitored for dose related adverse effects (see Section 4.4 and section 5.2).</p><p><em>&nbsp;</em><em><u>TPMT-deficient patients</u></em></p><p>Patients with inherited little or no thiopurine S-methyltransferase (TPMT) activity are at increased risk for severe azathioprine toxicity from conventional doses of azathioprine and generally require substantial dose reduction. The optimal starting dose for homozygous deficient patients has not been established (see Section 4.4 and Section 5.2).</p><p>Most patients with heterozygous TPMT deficiency can tolerate recommended azathioprine doses, but some may require dose reduction. Genotypic and phenotypic tests of TPMT are available (see Section 4.4 and Section 5.2).</p><p><u>&nbsp;Interactions with other medicinal products</u></p><p>When xanthine oxidase inhibitors, such as allopurinol, and azathioprine are administered concomitantly it is essential that only 25% of the usual dose of azathioprine is given since allopurinol decreases the rate of catabolism of azathioprine (see Section 4.5).</p><p><em>Patients with NUDT15 variant </em></p><p>Patients with inherited mutated NUDT15 gene are at increased risk for severe azathioprine toxicity (see 4.4). These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (see 4.4). Genotypic testing of NUDT15 variants may be considered before initiating azathioprine therapy. In any case, close monitoring of blood counts is necessary.</p><p><u>&nbsp;Method of Administration </u></p><p>For oral use.</p><p>Azathioprine may be taken with food or on an empty stomach, but patients should standardise the method of administration. Some patients experience nausea when first given azathioprine. With oral administration, nausea appears to be relieved by administering the tablets after meals. However, administration of azathioprine tablets after meals may reduce oral absorption, therefore monitoring for therapeutic efficacy should be considered after administration in this way (see Section 4.8).</p><p>The dose should not be taken with milk or dairy products (see Section 4.5). Azathioprine should be taken at least 1 hour before or 2 hours after milk or dairy products (see Section 5.2).</p><ul><li>&nbsp; Imuran is a cytotoxic drug. Follow applicable special handling and disposal procedures (see section 6.6).</li><li>&nbsp;Tablets should be swallowed whole.</li><li>&nbsp; The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</li><li>&nbsp;If tablet must be cut or crushed, this should be done by a professional trained personal experienced in safe handling of hazardous drugs using an appropriate equipment and safety procedures.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to azathioprine or to any of the excipients listed in section 6.1. 
Hypersensitivity to 6-mercaptopurine should alert the prescriber to probable hypersensitivity to azathioprine.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, it is recommended that patients do not receive live organism vaccines until at least 3 months after the end of their treatment with azathioprine (see Section 4.5).</p><p>Co-administration of ribavirin and azathioprine is not advised. Ribavirin may reduce efficacy and increase toxicity of azathioprine (see Section 4.5).</p><p><u>Monitoring</u></p><p>There are potential hazards in the use of azathioprine. It should be prescribed only if the patient can be adequately monitored for toxic effects throughout the duration of therapy.</p><p>Particular care should be taken to monitor haematological response and to reduce the maintenance dosage to the minimum required for clinical response.</p><p>It is suggested that during the first eight weeks of therapy, complete blood counts, including platelets, should be performed weekly or more frequently if high dosage is used or if severe renal and/or hepatic disorder is present. The blood count frequency may be reduced later in therapy, but it is suggested that complete blood counts are repeated monthly, or at least at intervals of no longer than three months.</p><p>At the first signs of an abnormal fall in blood counts, treatment should be interrupted immediately as leucocytes and platelets may continue to fall after treatment is stopped.</p><p>Patients receiving azathioprine should be instructed to report immediately any evidence of infection, unexpected bruising or bleeding or other manifestations of bone marrow depression. Bone marrow suppression is reversible if azathioprine is withdrawn early enough.</p><p>Azathioprine is hepatotoxic and liver function tests should be routinely monitored during treatment. More frequent monitoring may be advisable in those with pre-existing liver disease or receiving other potentially hepatotoxic therapy. The patient should be instructed to discontinue azathioprine immediately if jaundice becomes apparent.</p><p>There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid bone marrow depression following the initiation of treatment with azathioprine. This problem could be exacerbated by co-administration with medicinal products that inhibit TPMT, such as olsalazine, mesalazine or sulphasalazine. Also, a possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6&ndash;mercaptopurine (the active metabolite of azathioprine) in combination with other cytotoxics (see Section 4.8. Some laboratories offer testing for TPMT deficiency, although these tests have not been shown to identify all patients at risk of severe toxicity. Therefore, close monitoring of blood counts is still necessary. The dosage of azathioprine may need to be reduced when this agent is combined with other medicinal products whose primary or secondary toxicity is myelosuppression (see Section 4.5).</p><p><u>&nbsp;Hypersensitivity</u></p><p>Patients suspected to have previously presented a hypersensitivity reaction to 6-mercaptopurine should not be recommended to use its pro-drug azathioprine, and vice-versa, unless the patient has been confirmed as hypersensitive to the culprit drug with allergological tests, and tested negative for the other.</p><p>Patients with NUDT15 variant</p><p>Patients with inherited mutated NUDT15 gene are at increased risk for severe azathioprine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy. They generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2). The frequency of NUDT15 c.415C&gt;T has an ethnic variability of approximately 10 % in East Asians, 4 % in Hispanics, 0.2 % in Europeans and 0 % in Africans. In any case, close monitoring of blood counts is necessary.</p><p><u>&nbsp;Renal and/or hepatic impairment</u></p><p>Caution is advised during the administration of azathioprine in patients with renal impairment and/or hepatic impairment. Consideration should be given to reducing the starting dosage in these patients and haematological response should be carefully monitored (see Section 4.2 and Section 5.2).</p><p><u>&nbsp;Lesch-Nyhan syndrome</u></p><p>Limited evidence suggests that azathioprine is not beneficial to patients with<br />hypoxanthine- guanine-phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). Therefore, given the abnormal metabolism in these patients, it is not prudent to recommend that these patients should receive azathioprine.</p><p><u>Neuromuscular blocking agents</u></p><p>Special care is necessary when azathioprine is given concomitantly with neuromuscular blocking agents such as atracurium, rocuronium, cisatracurium or suxamethonium (also known as succinylcholine) (see section 4.5). Anesthesiologists should check whether their patients are administered azathioprine prior to surgery.</p><p><u>&nbsp;Mutagenicity</u></p><p>Chromosomal abnormalities have been demonstrated in both male and female patients treated with azathioprine. It is difficult to assess the role of azathioprine in the development of these abnormalities.</p><p>Chromosomal abnormalities, which disappear with time, have been demonstrated in lymphocytes from the off-spring of patients treated with azathioprine. Except in extremely rare cases, no overt physical evidence of abnormality has been observed in the off-spring of patients treated with azathioprine (see section 4.6).</p><p>Azathioprine and long-wave ultraviolet light have been shown to have a synergistic clastogenic effect in patients treated with azathioprine for a range of disorders.</p><p><u>Carcinogenicity (see Section 4.8):</u></p><p>Patients receiving immunosuppressive therapy, including azathioprine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi&rsquo;s and non-Kaposi&rsquo;s) and uterine cervical cancer <em>in situ</em>. The increased risk appears to be related to the degree and duration of immunosuppression. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.</p><p>A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.</p><p>Patients receiving multiple immunosuppressive agents may be at risk of over-immunosuppression, therefore such therapy should be maintained at the lowest effective level.</p><p>As is usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited, and patients should wear protective clothing and use a sunscreen with a high protection factor.</p><p>Reports of hepatosplenic T-cell lymphoma have been received when azathioprine is used alone or in combination with anti-TNF agents or other immunosuppressants. Although most reported cases occurred in the IBD population, there have also been cases reported outside of this population (see section 4.8).</p><p><u>Macrophage activation syndrome: </u></p><p>Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of azathioprine. If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible, and treatment with azathioprine should be discontinued. Physicians should be attentive to symptoms of infection such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.</p><p><u>Varicella Zoster Virus Infection (see Section4.8)</u></p><p>Infection with varicella zoster virus (VZV; chickenpox and herpes zoster) may become severe during the administration of immunosuppressants. Caution should be exercised especially with respect to the following:</p><p>Before starting the administration of immunosuppressants, the prescriber should check to see if the patient has a history of VZV. Serologic testing may be useful in determining previous exposure. Patients who have no history of exposure should avoid contact with individuals with chickenpox or herpes zoster. If the patient is exposed to VZV, special care must be taken to avoid patients developing chickenpox or herpes zoster, and passive immunisation with varicella-zoster immunoglobulin (VZIG) may be considered.</p><p>If the patient is infected with VZV, appropriate measures should be taken, which may include antiviral therapy and supportive care.</p><p><u>&nbsp;Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>PML, an opportunistic infection caused by the JC virus, has been reported in patients receiving azathioprine with other immunosuppressive agents. Immunosuppressive therapy should be withheld at the first sign or symptoms suggestive of PML and appropriate evaluation undertaken to establish a diagnosis (see Section 4.8).</p><p><u>Hepatitis B (see Section 4.8) </u></p><p>Hepatitis B carriers (defined as patients positive for hepatitis B surface antigen [HBsAg] for more than six months), or patients with documented past HBV infection, who receive immunosuppressants are at risk of reactivation of HBV replication, with asymptomatic increases in serum HBV DNA and ALT levels. Local guidelines may be considered including prophylactic therapy with oral anti-HBV agents.</p><p><u>Neuromuscular agents </u></p><p>Special care is necessary when azathioprine is given concomitantly with neuromuscular acting agents like tubocurarine or succinylcholine. It can also potentiate the neuromuscular block that is produced by depolarising agents such as succinylcholine (<em>see section 4.5</em>). Patients should be advised to inform their anaesthesiologist of their treatment with azathioprine prior to surgery.</p><p><em><u>&nbsp;</u></em><u>Lactose</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Food, milk and dairy products</u></em></p><p>The administration of azathioprine with food may decrease systemic exposure slightly but this is unlikely to be of clinical significance (see Section 4.8). Therefore, azathioprine may be taken with food or on an empty stomach, but patients should standardise the method of administration. The dose should not be taken with milk or dairy products since they contain xanthine oxidase, an enzyme which metabolises 6&ndash;mercaptopurine and might therefore lead to reduced plasma concentrations of 6&ndash;mercaptopurine (see Section 4.2 and 5.2).</p><p><u>&nbsp;</u><em><u>Vaccines</u></em></p><p>The immunosuppressive activity of azathioprine could result in an atypical and potentially deleterious response to live vaccines. It is therefore recommended that patients do not receive live vaccines until at least 3 months after the end of their treatment with azathioprine (see Section 4.4.).</p><p>A diminished response to killed vaccines is likely and such a response to hepatitis B vaccine has been observed among patients treated with a combination of azathioprine and corticosteroids.</p><p>A small clinical study has indicated that standard therapeutic doses of azathioprine do not deleteriously affect the response to polyvalent pneumococcal vaccine, as assessed on the basis of mean anti-capsular specific antibody concentration.</p><p><u>&nbsp;Effect of concomitant medicinal products on azathioprine</u></p><p><em>&nbsp;Ribavirin</em></p><p>Ribavirin inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), leading to a lower production of the active 6-thioguanine nucleotides. Severe myelosuppression has been reported following concomitant administration of azathioprine and ribavirin; therefore co-administration is not advised (see Section 4.4. and Section 5.2).</p><p><em>&nbsp;Cytostatic/myelosuppressive agents</em> (see Section 4.4)</p><p>Where possible, concomitant administration of cytostatic agents, or medicinal products which may have a myelosuppressive effect, such as penicillamine, should be avoided. There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities, between azathioprine and co-trimoxazole.</p><p>There have been case reports suggesting that haematological abnormalities may develop due to the concomitant administration of azathioprine and ACE Inhibitors.</p><p>It has been suggested that cimetidine and indomethacin may have myelosuppressive effects which may be enhanced by concomitant administration of azathioprine.</p><p><em>&nbsp;Allopurinol/oxipurinol/thiopurinol and other xanthine oxidase inhibitors</em></p><p>Xanthine oxidase activity is inhibited by allopurinol, oxipurinol and thiopurinol which results in reduced conversion of biologically active 6-thioinosinic acid to biologically inactive 6-thiouric acid.</p><p>When allopurinol, oxipurinol and/or thiopurinol are given concomitantly with 6-mercaptopurine or azathioprine, the dose of 6-mercaptopurine and azathioprine should be reduced to 25% of the original dose (see Section 4.2).</p><p>Based on non-clinical data, other xanthine oxidase inhibitors, such as febuxostat, may prolong the activity of azathioprine possibly resulting in enhanced bone marrow suppression. Concomitant administration is not recommended as data are insufficient to determine an adequate dose reduction of azathioprine.</p><p><em>&nbsp;Aminosalicylate</em></p><p>There is <em>in vitro</em> and <em>in vivo</em> evidence that aminosalicylate derivatives (e.g. olsalazine, mesalazine or sulfasalazine) inhibit the TPMT enzyme. Therefore, lower doses of azathioprine may need to be considered when administered concomitantly with aminosalicylate derivatives (see Section 4.4).</p><p><em>&nbsp;Methotrexate</em></p><p>Methotrexate (20 mg/m<sup>2</sup> orally) increased 6-mercaptopurine AUC by approximately 31% and methotrexate (2 or 5 g/m<sup>2</sup> intravenously) increased 6-mercaptopurine AUC by 69 and 93%, respectively.</p><p><em>Infliximab</em></p><p>An interaction has been observed between azathioprine and infliximab. Patients receiving ongoing azathioprine experienced transient increases in 6-TGN (6-thioguanine nucleotide, an active metabolite of azathioprine) levels and a decrease in the mean leukocyte count in the initial weeks following infliximab infusion, which returned to previous levels after 3 months.</p><p><u>&nbsp;Neuromuscular blocking agents</u></p><p>There is clinical evidence that azathioprine antagonises the effect of non-depolarising muscle relaxants. Experimental data confirm that azathioprine reverses the neuromuscular blockade produced by non-depolarising agents (such as tubocurarine) and show that azathioprine potentiates the neuromuscular blockade produced by depolarising agents, such as succinylcholine (see section 4.4). There is considerable variation in the potency of this interaction.</p><p><u>&nbsp;Effect of azathioprine on other medicinal products</u></p><p><em>Anticoagulants</em></p><p>Inhibition of the anticoagulant effect of warfarin and acenocoumarol has been reported when co-administered with azathioprine; therefore, higher doses of the anticoagulant may be needed. It is recommended that coagulation tests are closely monitored when anticoagulants are concurrently administered with azathioprine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p>The specific effect of azathioprine therapy on human fertility is unknown..</p><p><u>&nbsp;Pregnancy:</u></p><p>Substantial transplacental and transamniotic transmission of azathioprine and its metabolites from the mother to the foetus have been shown to occur.</p><p>Azathioprine should not be given to patients who are pregnant or likely to become pregnant in the near future without careful assessment of risk versus benefit.</p><p>Evidence of the teratogenicity of azathioprine in man is equivocal. As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving azathioprine.</p><p><em>&nbsp;Mutagenicity</em></p><p>Chromosomal abnormalities, which disappear with time, have been demonstrated in lymphocytes from the off-spring of patients treated with Imuran.&nbsp; Except in extremely rare cases, no overt physical evidence of abnormality has been observed in the off-spring of patients treated with Imuran.&nbsp; Azathioprine and long‑wave ultraviolet light have been shown to have a synergistic clastogenic effect in patients treated with azathioprine for a range of disorders (see section 4.4).</p><p>There have been reports of premature birth and low birth weight following maternal exposure to azathioprine, particularly in combination with corticosteroids. There have also been reports of spontaneous abortion following either maternal or paternal exposure.</p><p>Leukopenia and/or thrombocytopenia have been reported in a proportion of neonates whose mothers took azathioprine throughout their pregnancies. Extra care in haematological monitoring is advised during pregnancy.</p><p><u>&nbsp;Breast-feeding:</u></p><p>6-mercaptopurine has been identified in the colostrum and breast-milk of women receiving azathioprine treatment. Available data has shown that the excreted levels in breast-milk are low. From the limited available data, the risk to newborns/infants is considered to be unlikely but cannot be excluded.</p><p>It is recommended that women receiving azathioprine should avoid breastfeeding unless the benefits outweighs the potential risks.</p><p>If a decision is made to breastfeed, because 6-mercaptopurine is a strong immunosuppressant, the breastfed infant should be closely monitored for signs of immunosuppression, leukopenia, thrombocytopenia, hepatotoxicity, pancreatitis or other symptoms of 6-mercaptopurine exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of azathioprine on driving performance or the ability to operate machinery. A detrimental effect on these activities cannot be predicted from the pharmacology of azathioprine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>For this product there is no modern clinical documentation which can be used as support for determining the frequency of undesirable effects. Undesirable effects may vary in their incidence depending on the indication.</p><p>The most important adverse reactions include bone marrow depression, most frequently expressed as leukopenia, thrombocytopenia, or anaemia; viral, fungal and bacterial infections; life-threatening liver injury; hypersensitivity, Stevens-Johnson syndrome and toxic epidermal necrolysis</p><p><u>Tabulated list of adverse reactions</u></p><p>The following convention has been utilised for the classification of frequency:</p><p>Very common &ge;1/10</p><p>Common &ge;1/100 and &lt;1/10</p><p>Uncommon &ge;1/1000 and &lt;1/100</p><p>Rare &ge;1/10,000 and &lt;1/1000</p><p>Very rare &lt;1/10,000</p><p>Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Body S</strong><strong>ystem</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Side effects</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Viral, fungal, and bacterial infections in transplant patients receiving azathioprine in combination with other immunosuppressants</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Viral, fungal, and bacterial infections in other patient populations</p></td></tr><tr><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Cases of JC virus associated PML have been reported following the use of azathioprine in combination with other immunosuppressants (see Section 4.4).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Neoplasms benign, malignant, and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Neoplasms including lymphoproliferative disorders, skin cancers (melanomas and<br />non-melanomas), sarcomas (Kaposi&rsquo;s and non-Kaposi&rsquo;s) and uterine cervical cancer <em>in situ</em>, acute myeloid leukaemia, and myelodysplasia (see Section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatosplenic T-cell lymphoma (see Section 4.4<em>)</em>.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bone marrow depression, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia, aplastic anemia, megaloblastic anaemia, erythroid hypoplasia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome and toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Reversible pneumonitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>colitis, diverticulitis, and bowel perforation reported in transplant population, severe diarrhoea in inflammatory bowel disease population</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cholestasis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Life-threatening liver injury</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Acute febrile neutrophilic dermatosis (Sweet&rsquo;s syndrome), photosensitivity</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em>Infections and infestations</em></p><p>Patients receiving azathioprine alone or in combination with other immunosuppressants, particularly corticosteroids, have shown increased susceptibility to viral, fungal and bacterial infections, including severe or atypical infection, and reactivation with VZV, hepatitis B and other infectious agents (see Section 4.4).</p><p><em>&nbsp;Neoplasms benign, malignant, and unspecified (including cysts and polyps)</em></p><p>The risk of developing non-Hodgkin&rsquo;s lymphomas and other malignancies, notably skin cancers (melanoma and non-melanomas), sarcomas (Kaposi&rsquo;s and non-Kaposi&rsquo;s) and uterine cervical cancer <em>in situ</em>, is increased in patients who receive immunosuppressants, particularly in transplant recipients receiving aggressive treatment and such therapy should be maintained at the lowest effective levels. The increased risk of developing non-Hodgkin&rsquo;s lymphomas in immunosuppressed rheumatoid arthritis patients compared with the general population appears to be related at least in part to the disease itself.</p><p>There have been rare reports of acute myeloid leukaemia and myelodysplasia (some in association with chromosomal abnormalities).</p><p><em>&nbsp;Blood and lymphatic system disorders</em></p><p>Azathioprine may be associated with a dose-related, generally reversible, depression of bone marrow function, most frequently expressed as leukopenia, but also sometimes as anaemia and thrombocytopenia and rarely as agranulocytosis, pancytopenia, and aplastic anaemia. These occur particularly in patients predisposed to myelotoxicity, such as those with TPMT deficiency and renal or hepatic insufficiency and in patients failing to reduce the dose of azathioprine when receiving concurrent allopurinol therapy.</p><p>Reversible, dose-related increases in mean corpuscular volume and red cell haemoglobin content have occurred in association with azathioprine therapy. Megaloblastic bone marrow changes have also been observed but severe megaloblastic anaemia and erythroid hypoplasia are rare.</p><p><em>&nbsp;Immune system disorders</em></p><p>Several different clinical syndromes, which appear to be idiosyncratic manifestations of hypersensitivity, have been described occasionally following administration of azathioprine tablets and injection. Clinical features include general malaise, dizziness, nausea, vomiting, diarrhoea, fever, rigors, exanthema, rash, <u>erythema nodosum</u>, vasculitis, myalgia, arthralgia, hypotension, renal dysfunction, hepatic dysfunction, and cholestasis (see 4.8 - Hepatobiliary disorders).</p><p>In many cases, rechallenge has confirmed an association with azathioprine.</p><p>Immediate withdrawal of azathioprine and institution of circulatory support where appropriate have led to recovery in the majority of cases.</p><p>Other marked underlying pathology has contributed to the very rare deaths reported.</p><p>Following a hypersensitivity reaction to azathioprine tablets and injection, the necessity for continued administration should be carefully considered on an individual basis.</p><p><em>&nbsp;Gastrointestinal disorders</em></p><p>Some patients experience nausea when first given azathioprine. With oral administration, nausea appears to be relieved by administering the tablets after meals. However, administration of azathioprine tablets after meals may reduce oral absorption, therefore monitoring for therapeutic efficacy should be considered after administration in this way (see Section 4.2, 4.5 and 5.2).</p><p>Serious complications, including colitis, diverticulitis, and bowel perforation, have been described in transplant recipients receiving immunosuppressive therapy. However, the aetiology is not clearly established, and high-dose corticosteroids may be implicated. Severe diarrhoea, recurring on rechallenge, has been reported in patients treated with azathioprine for inflammatory bowel disease. The possibility that exacerbation of symptoms might be related to the medicinal product should be borne in mind when treating such patients.</p><p>Pancreatitis has been reported in a small percentage of patients on azathioprine therapy, particularly in renal transplant patients and those diagnosed as having inflammatory bowel disease.</p><p><em>&nbsp;Hepatobiliary disorders</em></p><p>Cholestasis and deterioration of liver function have occasionally been reported in association with azathioprine therapy and are usually reversible on withdrawal of therapy. This may be associated with symptoms of a hypersensitivity reaction (see Immune system disorders).</p><p>Rare, but life-threatening hepatic damage associated with chronic administration of azathioprine has been described primarily in transplant patients. Histological findings include sinusoidal dilatation, peliosis hepatis, veno-occlusive disease and nodular regenerative hyperplasia. In some cases withdrawal of azathioprine has resulted in either a temporary or permanent improvement in liver histology and symptoms.</p><p><em>&nbsp;Skin and subcutaneous tissue disorders</em></p><p>Hair loss has been described on a number of occasions in patients receiving azathioprine and other immunosuppressive agents. In many instances the condition resolved spontaneously despite continuing therapy.</p><p><u>&nbsp;Paediatric population</u></p><p>Frequency, type, and severity of adverse reactions in children are expected to be the same as in adults.</p><p><u>To reports any side effect(s):</u></p><p><strong>&nbsp;Saudi Arabia:&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&bull;&nbsp;&nbsp; &nbsp;The National Pharmacovigilance Centre (NPC):<br />-&nbsp;&nbsp; &nbsp;SFDA Call Center: 19999<br />-&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa<br />-&nbsp;&nbsp; &nbsp;Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><br /><strong>-Other GCC States:</strong><strong>&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>- Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p>Unexplained infection, ulceration of the throat, bruising and bleeding are the main signs of overdosage with azathioprine and result from bone marrow depression which may be maximal after 9 to14 days. These signs are more likely to be manifest following chronic overdosage, rather than after a single acute overdose. There has been a report of a patient who ingested a single overdose of 7.5g of azathioprine. The immediate toxic effects of this overdose were nausea, vomiting and diarrhoea, followed by mild leukopenia and mild abnormalities in liver function. Recovery was uneventful.</p><p><u>&nbsp;Treatment</u></p><p>As there is no specific antidote, blood counts should be closely monitored and general supportive measures, together with appropriate blood transfusion, instituted if necessary. Active measures (such as the use of activated charcoal) may not be effective in the event of azathioprine overdose unless the procedure can be undertaken within 60 minutes of ingestion.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>The value of dialysis in patients who have taken an overdose of azathioprine is not known, though azathioprine is partially dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: <em>Antineoplastic and Immunomodulating agents</em>, ATC code: <em>L04AX01</em></p><p>Azathioprine is an imidazole derivative of 6-mercaptopurine (6-MP).&nbsp; It is rapidly broken down <em>in vivo </em>into 6-MP and a methylnitroimidazole moiety.&nbsp; The 6-MP readily crosses cell membranes and is converted intracellularly into a number of purine thioanalogues, which include the main active nucleotide, thioinosinic acid.&nbsp; The rate of conversion varies from one person to another.&nbsp; Nucleotides do not traverse cell membranes and therefore do not circulate in body fluids.&nbsp; Irrespective of whether it is given directly or is derived <em>in vivo </em>from azathioprine, 6-MP is eliminated mainly as the inactive oxidised metabolite thiouric acid.&nbsp; This oxidation is brought about by xanthine oxidase, an enzyme which is inhibited by allopurinol.&nbsp; The activity of the methylnitroimidazole moiety has not been defined clearly.&nbsp; However, in several systems it appears to modify the activity of azathioprine as compared with that of 6-MP.&nbsp; Determinations of plasma concentrations of azathioprine or 6-MP have no prognostic value as regards effectiveness or toxicity of these compounds.</p><p>While the precise modes of action remain to be elucidated, some suggested mechanisms include:</p><p><br />1.the release of 6-MP which acts as a purine antimetabolite.</p><p>2.the possible blockade of-SH groups by alkylation.</p><p>3.the inhibition of many pathways in nucleic acid biosynthesis, hence preventing proliferation of cells involved in determination and amplification of the immune response.</p><p>4.damage to deoxyribonucleic acid (DNA) through incorporation of purine thio-analogues.</p><p>&nbsp;</p><p>Because of these mechanisms, the therapeutic effect of Imuran may be evident only after several weeks or months of treatment.</p><p>Imuran appears to be well absorbed from the upper gastro-intestinal tract.</p><p>Studies in mice with <sup>35</sup>S-azathioprine showed no unusually large concentration in any particular tissue, but there was very little <sup>35</sup>S found in brain.</p><p>Plasma levels of azathioprine and 6-mercaptopurine do not correlate well with the therapeutic efficacy or toxicity of Imuran.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Azathioprine is well absorbed following oral administration. Although there are no food effect studies with azathioprine, pharmacokinetic studies with 6-mercaptopurine have been conducted that are relevant to azathioprine. The mean relative bioavailability of 6-mercaptopurine was approximately 27% lower following administration with food and milk compared to an overnight fast. 6-mercaptopurine is not stable in milk due to the presence of xanthine oxidase (30% degradation within 30 minutes) (<em>see Section 4.2</em>). Azathioprine may be taken with food or on an empty stomach, but patients should standardise the method of administration. The dose should not be taken with milk or dairy products (<em>see Section 4.2</em>).</p><p>After oral administration of [<sup>35</sup>S]-azathioprine, the maximum plasma radioactivity occurs at 1-2 hours and decays with a half-life of 4-6 hours.&nbsp; This is not an estimate of the half-life of azathioprine itself, but reflects the elimination from plasma of azathioprine and the [<sup>35</sup>S]-containing metabolites of the drug. As a consequence of the rapid and extensive metabolism of azathioprine, only a fraction of the radioactivity measured in plasma is comprised of unmetabolised drug.&nbsp; Studies in which the plasma concentration of azathioprine and 6-mercaptopurine have been determined following intravenous administration of azathioprine have estimated the mean plasma T<sup>1</sup>/<sub>2</sub> for azathioprine to be in the range of 6-28 minutes and the mean plasma T<sup>1</sup>/<sub>2</sub> for 6-mercaptopurine to be in the range 38-114 minutes after i.v. administration of the drug.</p><p>Azathioprine is principally excreted as 6-thiouric uric acid in the urine.&nbsp; 1-methyl-4-nitro-5-thioimidazole has also been detected in urine as a minor excretory product.&nbsp; This would indicate that, rather than azathioprine being exclusive cleaved by nucleophilic attack at the 5-position of the nitroimidazole ring to generate 6-mercaptopurine and 1-methyl-4-nitro-5-(S-glutathionyl)imidazole.&nbsp; A small proportion of the drug may be cleaved between the S atom and the purine ring.&nbsp; Only a small amount of the dose of azathioprine administered is excreted unmetabolised in the urine.</p><p><u>Biotransformation</u></p><p><em>Thiopurine S-Methyl Transferase (TPMT) </em></p><p>TPMT activity is inversely related to red blood cell 6-mercaptopurine derived thioguanine nucleotide concentration, with higher thioguanine nucleotide concentrations resulting in greater reductions in white blood cell and neutrophil counts. Individuals with TPMT deficiency develop very high cytotoxic thioguanine nucleotide concentrations.</p><p>Genotypic testing can determine the allelic pattern of a patient. Currently, 3 alleles &mdash;TPMT*2, TPMT*3A and TPMT*3C &mdash; account for about 95% of individuals with reduced levels of TPMT activity. Approximately 0.3% (1:300) of patients have two non-functional alleles (homozygous-deficient) of the TPMT gene and have little or no detectable enzyme activity. Approximately 10% of patients have one TPMT non-functional allele (heterozygous) leading to low or intermediate TPMT activity and 90% of individuals have normal TPMT activity with two functional alleles. There may also be a group of approximately 2% who have very high TPMT activity. Phenotypic testing determines the level of thiopurine nucleotides or TPMT activity in red blood cells and can also be informative (see section 4.4).</p><p>&nbsp;</p><p><u>Special Patient Populations</u></p><p><em>&nbsp;Paediatric population - Overweight children</em></p><p>In a US clinical study, 18 children (aged 3 to 14 years) were evenly divided into two groups; either a weight to height ratio above or below the 75th percentile. Each child was on maintenance treatment of 6-mercaptopurine and the dosage was calculated based on their body surface area. The mean AUC (0-&infin;) of 6-mercaptopurine in the group above the 75th percentile was 2.4 times lower than that for the group below the 75th percentile. Therefore, children considered to be overweight may require azathioprine doses at the higher end of the dose range and close monitoring of response to treatment is recommended (see section 4.2).</p><p><em>Patients with renal impairment</em></p><p>Studies with azathioprine have shown no difference in 6-mercaptopurine pharmacokinetics in uremic patients compared to renal transplant patients. Since little is known about the active metabolites of azathioprine in renal impairment, consideration should be given to reducing the dosage in patients with impaired renal function (see section 4.2).</p><p>Azathioprine and/or its metabolites are eliminated by haemodialysis, with approximately 45% of radioactive metabolites eliminated during dialysis of 8 hours.</p><p><em>Patients with hepatic impairment</em></p><p>A study with azathioprine was performed in three groups of renal transplant patients: those without liver disease, those with hepatic impairment (but no cirrhosis) and those with hepatic impairment and cirrhosis. The study demonstrated that 6-mercaptopurine exposure was 1.6 times higher in patients with hepatic impairment (but no cirrhosis) and 6 times higher in patients with hepatic impairment and cirrhosis, compared to patients without liver disease. Therefore, consideration should be given to reducing the dosage in patients with impaired hepatic function (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Teratogenicity</u></p><p>Studies in pregnant rats, mice and rabbits using azathioprine in dosages from 5 to 15&nbsp;mg/kg body weight/day over the period of organogenesis have shown varying degrees of foetal abnormalities.&nbsp; Teratogenicity was evident in rabbits at 10&nbsp;mg/kg body weight/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, pregelatinised starch, maize starch, stearic acid, magnesium sterate, methylhydroxylpropyl cellulose, polyethylene glycol 400, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp; Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister strips in a pack.</p><p>Pack size: 28, 30, 56, 60, 100 and 1000 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Safe handling</u></p><p>Health professionals who handle uncoated azathioprine tablets should follow guidelines for the handling of cytotoxic medicinal products according to prevailing local recommendations and/or regulations.</p><p>Provided that the film-coating is intact, there is no risk in handling film-coated azathioprine tablets.</p><p>Film-coated azathioprine tablets should not be divided and, provided the coating is intact, no additional precautions are required when handling them.</p><ul><li>&nbsp;Imuran is a cytotoxic drug; considered as human carcinogen.</li><li>&nbsp;In healthcare settings, use designated area for medication storage and restrict access to only authorized personal</li><li>&nbsp;To minimize the risk of dermal exposure, wear chemotherapy gloves and sleeve covers when handling Imuran. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking and, and storing within a facility.</li><li>&nbsp;For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container.</li><li>&nbsp;The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</li><li>&nbsp;Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>&nbsp; When manipulations are necessary such as compounding, crushing, cutting, or splitting; should be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</li><li>Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn.</li><li>When clinically appropriate, add liquid or moist products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.</li><li>&nbsp;For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out.</li><li>&nbsp;Personnel who are pregnant should avoid exposure to crushed or broken coated tablets.</li></ul><p><u>Disposal</u></p><p>Azathioprine tablets should be disposed of in a manner appropriate to the prevailing local regulatory requirements for the destruction of dangerous substances.</p><ul><li>&nbsp;Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</li><li>&nbsp;Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face.</li><li>&nbsp;For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags.</li><li>&nbsp;In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary.</li><li>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
3016 Lake Drive,
Citywest Business Campus,
Dublin 24, Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marche 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>